ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
-0,05%
Bitcoin
66.008,09
0,00%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Poseida Therapeutics Inc (PSTX)

  7. Poseida Therapeutics Inc (PSTX) News

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PSTX
DatumZeitQuelleÜberschriftSymbolFirma
03/06/202422h05PR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
14/05/202422h05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
09/05/202415h00PR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
06/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
02/05/202403h30PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
01/05/202421h25AllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
01/05/202415h00PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
18/04/202414h00PR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
17/04/202415h00PR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
08/04/202418h00PR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
01/04/202422h05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
25/03/202421h05PR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
19/03/202421h05PR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
13/03/202421h05PR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
07/03/202422h07PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
07/03/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
04/03/202423h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
04/03/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
04/03/202422h05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
08/02/202422h10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTXPoseida Therapeutics Inc
04/01/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
04/01/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
04/01/202414h00PR Newswire (US)Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:PSTXPoseida Therapeutics Inc
11/12/202316h31Dow Jones NewsPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer TreatmentNASDAQ:PSTXPoseida Therapeutics Inc
11/12/202312h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
10/12/202318h00PR Newswire (US)Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
09/11/202322h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
09/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PSTX

Kürzlich von Ihnen besucht

BIT
UI113B
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten